Cover Image
市場調查報告書

肺動脈栓塞:開發中產品分析

Pulmonary Embolism - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213109
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
肺動脈栓塞:開發中產品分析 Pulmonary Embolism - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 51 Pages
簡介

所謂肺動脈栓塞,是指肺內部的血管(肺動脈)突然(通常因血塊)阻塞的疾病。主要症狀是呼吸急促和胸痛、咳嗽、腿部疼痛和膨脹、過度發汗、心律的劇增和心律不整,暈眩等。主要易罹病素質,有高血壓和心血管疾病等。治療方法為抗凝固藥和血栓溶解藥等。

本報告提供全球各國治療肺動脈栓塞(肺動脈栓塞症)所用之開發中產品開發情形相關分析、提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,再加上主要企業簡介、主要藥物概要、最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

肺動脈栓塞概要

治療藥的開發

  • 肺動脈栓塞開發中產品:概要
  • 肺動脈栓塞開發中產品:比較分析

各企業開發中的肺動脈栓塞治療藥

大學/研究機關研究中的肺動脈栓塞治療藥

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

肺動脈栓塞治療藥:開發中的產品一覽(各企業)

肺動脈栓塞治療藥:研究中的產品一覽(各大學/研究機關)

肺動脈栓塞治療藥的開發企業

  • Accu-Break Pharmaceuticals, Inc.
  • Dong-A Socio Holdings Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.

肺動脈栓塞:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

肺動脈栓塞治療藥:開發暫停的產品

肺動脈栓塞治療藥:開發中止的產品

肺動脈栓塞相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8359IDB

Summary

Global Markets Direct's, 'Pulmonary Embolism - Pipeline Review, H2 2016', provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
  • The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pulmonary Embolism Overview
  • Therapeutics Development
    • Pipeline Products for Pulmonary Embolism - Overview
    • Pipeline Products for Pulmonary Embolism - Comparative Analysis
  • Pulmonary Embolism - Therapeutics under Development by Companies
  • Pulmonary Embolism - Therapeutics under Investigation by Universities/Institutes
  • Pulmonary Embolism - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Pulmonary Embolism - Products under Development by Companies
  • Pulmonary Embolism - Products under Investigation by Universities/Institutes
  • Pulmonary Embolism - Companies Involved in Therapeutics Development
    • Accu-Break Pharmaceuticals, Inc.
    • Dong-A Socio Holdings Co. Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Genentech, Inc.
  • Pulmonary Embolism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-023725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenecteplase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMS-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • warfarin potassium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pulmonary Embolism - Dormant Projects
  • Pulmonary Embolism - Discontinued Products
  • Pulmonary Embolism - Product Development Milestones
    • Featured News & Press Releases
      • Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
      • Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials
      • Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy
      • Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting
      • Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
      • Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
      • Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
      • Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014
      • Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
      • Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
      • May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism
      • Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention
      • Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE
      • Dec 03, 2013: New Data to be Presented on Bayer's Xarelto Single-Drug Solution for the Treatment and Prevention of Recurrent Pulmonary Embolism and Deep Vein Thrombosis
      • Sep 20, 2013: Pooled Analysis Confirms XARELTO has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pulmonary Embolism, H2 2016
  • Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals, Inc., H2 2016
  • Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pulmonary Embolism - Pipeline by Genentech, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pulmonary Embolism - Dormant Projects, H2 2016
  • Pulmonary Embolism - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pulmonary Embolism, H2 2016
  • Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top